Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma

Alberto Martini(The University of Texas MD Anderson Cancer Center), John P. Sfakianos(Mount Sinai Medical Center), Elona Poltiyelova(Icahn School of Medicine at Mount Sinai), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Bart S. Ferket(PragmatIC (United Kingdom)), Zeynep Gul(Zonguldak Bülent Ecevit University), Nikhil Waingankar(Icahn School of Medicine at Mount Sinai), Jorge Daza(Icahn School of Medicine at Mount Sinai), John R. Heard(Icahn School of Medicine at Mount Sinai)
British Journal of Urology
February 25, 2019
10.1111/bju.14719
Cited by 44

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786